Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Cediranib in combination with olaparib for recurrent platinum-resistant ovarian cancer – fourth line or greater	Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Dapagliflozin for chronic heart failure with reduced ejection fraction	Dapagliflozin (Forxiga; BMS512148; Farxiga; dapagliflozin propanediol monohydrate)	Heart failure (HF)	Cardiovascular System	2019	View \| Download
Dapagliflozin for heart failure with preserved ejection fraction	Dapagliflozin (Forxiga; BMS512148; Farxiga; dapagliflozin propanediol monohydrate)	Heart failure (HF)	Cardiovascular System	2019	View \| Download
Daratumumab (subcutaneous injection) for multiple myeloma	Daratumumab (Darzalex; JNJ-54767414)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2019	View \| Download
Diroximel fumarate for relapsing-remitting multiple sclerosis	Diroximel fumarate (BIIB098; ALKS-8700)	Multiple sclerosis (MS)	Neurology	2019	View
Dupilumab for children aged 6 to less than 12 years with severe atopic dermatitis	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Atopic dermatitis	Dermatology	2019	View \| Download
Durvalumab for recurrent or metastatic squamous cell carcinoma of the head and neck – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Head and neck cancer	Head and Neck Cancer	2019	View \| Download
Durvalumab in addition to chemotherapy for metastatic non-small-cell lung cancer - first line	Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Durvalumab in combination with tremelimumab for unresectable hepatocellular carcinoma – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2019	View \| Download
Durvalumab with or without tremelimumab in addition to platinum based chemotherapy for extensive-stage disease small-cell lung cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2019	View \| Download